Work

Neoadjuvant chemotherapy plus anlotinib in the treatment of resectable head and neck squamous cell carcinoma: A pilot phase II trial

Year: 2025

Type: article

Abstract: Neoadjuvant chemotherapy plus anlotinib in the treatment of resectable head and neck squamous cell carcinoma: A pilot phase II trialHead and neck squamous cell carcinoma (HNSCC) continues to be a major global health challenge, with limited survival improvements for patients with locally advanced (LA) or recurrent (R) disease [1].Anlotinib, a novel orally administered small-molecule tyrosine kinase inhibitor (TKI) developed in China, targets a wide range of receptor tyrosine kinases (RTKs) [2].Our previous studies have also manifested that anlotinib remarkably inhibited the proliferation of HNSCC cells both in vitro and in vivo, and presented promising clinical antitumor efficacy and tolerable safety profile in patients with oral squamous cell carcinoma (OSCC) [3,4].This prospective trial was designed to evaluate the clinical efficacy and safety of anlotinib combined with paclitaxel and cisplatin (TP) neoadjuvant therapy in patients with resectable HNSCC.Additionally, the mechanisms underlying the effects of anlotinib and neoadjuvant chemotherapy on HNSCC were investigated through spatial transcriptomics (STs) and multiplex immunohistochemistry (mIHC).

Source: 癌症：英文版

DOI: 10.1002/cac2.70006